The Cerba Research team will be attending ESCCA 2023 in Utrecht! Meet our scientists Amber Baele, Feyzâ Matisli, Eva Van Lombergen, and Silke De Waele, and discover the various posters they will present there.

Complex flow cytometry is critical for today’s personalized medicine. With the breakthrough of cellular immune therapies, such as CAR+ T, flow cytometry became a critical platform for clinical laboratories, drug developers, and manufacturers. We will be sharing how Cerba Research is transforming the field of clinical flow cytometry with advanced methods and cutting-edge technologies. Cerba Research develops and validates custom-made flow cytometry panels used in flow cytometry testing for clinical trials, ranging from phase I to phase III.

Discover our posters at ESCCA 2023

Implementation of Cytek® Aurora instruments in clinical trials: A multi-step process including performance qualification and standardization

By Amber Baele (Cerba Research)

Development and validation of flow cytometry assays for autologous and allogenic CAR T in global clinical programs

By Eva Van Lombergen (Cerba Research)

Validation of a Flow Cytometry Assay on Cytek® Aurora to Monitor Immune Cells in Peripheral Whole Blood for Clinical Trials

By Feyzâ Matisli (Cerba Healthcare Belgium – Division CRI)

Upscaling of a Clinical Flow Cytometry Laboratory

By Feyzâ Matisli (Cerba Healthcare Belgium – Division CRI)

Creating a flow cytometry sample management and reporting system starting from Instrument Manager™

By Silke De Waele (Cerba Healthcare Belgium – Division CRI)